Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study

Abstract.  Holme I, Fellström BC, Jardin AG, Schmieder RE, Zannad F, Holdaas H (Oslo University Hospital, Ullevål, Oslo, Norway; British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, UK; University Hospital, Erlangen, Germany; Centre d`Investigation Clinique; Centre Hospitalier Universitaire, and Nancy Université, Nancy, France; and Oslo University Hospital, Oslo, Norway). Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study. J Intern Med 2012; 271: 463–471.

[1]  W. Suki,et al.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. , 2007, Kidney international.

[2]  C. Zoccali,et al.  Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. , 2005, Journal of the American Society of Nephrology : JASN.

[3]  B. Stengel,et al.  A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  F. Zannad,et al.  Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study , 2005, Current controlled trials in cardiovascular medicine.

[5]  A. Jardine,et al.  Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[7]  F. Zannad,et al.  Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  J. Bragg-Gresham,et al.  Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. , 2006, Kidney international.

[9]  R. Ruthazer,et al.  Predicting six-month mortality for patients who are on maintenance hemodialysis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[10]  R. Foley,et al.  Left ventricular hypertrophy in the renal patient. , 2001, Journal of the American Society of Nephrology : JASN.

[11]  S. Davies,et al.  End-stage renal disease: A new comorbidity index for estimating mortality risk in ESRD , 2010, Nature Reviews Nephrology.

[12]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.

[13]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[14]  F. Zannad,et al.  Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study , 2007, Kidney and Blood Pressure Research.

[15]  N. Isbel,et al.  Modification of cardiovascular risk in hemodialysis patients: An evidence‐based review , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[16]  N. Levin,et al.  Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.